Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.

Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, Ruiz C.

J Pathol. 2018 May;245(1):74-84. doi: 10.1002/path.5052. Epub 2018 Apr 2.

PMID:
29484655
2.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

3.

Primary synovial cell sarcoma of the kidney: case report and review of the literature.

Vedana M, Fuenfschilling M, Tzankov A, Zellweger T.

Case Rep Oncol. 2015 Mar 3;8(1):128-32. doi: 10.1159/000379740. eCollection 2015 Jan-Apr.

4.

Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.

Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A, Ruiz C, Dirnhofer S, Bubendorf L, Rentsch CA.

Prostate. 2015 May;75(6):585-92. doi: 10.1002/pros.22939. Epub 2015 Jan 13.

PMID:
25585936
5.

Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens.

Vlajnic T, Oeggerli M, Rentsch C, Püschel H, Zellweger T, Thalmann GN, Ruiz C, Bubendorf L.

Virchows Arch. 2014 Dec;465(6):637-42. doi: 10.1007/s00428-014-1665-8. Epub 2014 Oct 17.

PMID:
25323812
6.

Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up.

Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA.

Virchows Arch. 2014 Dec;465(6):629-36. doi: 10.1007/s00428-014-1656-9. Epub 2014 Oct 1.

PMID:
25269630
7.

MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.

8.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31. doi: 10.1038/pcan.2013.62. Epub 2014 Jan 28.

9.

MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.

Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.

Int J Cancer. 2014 Jul 1;135(1):19-26. doi: 10.1002/ijc.28647. Epub 2013 Dec 9.

10.

[Renal masses and indication to nephrectomy: preoperative assessment and clinical presentation of five cases].

Vedana M, Geisler S, Zellweger T, Gasser T.

Rev Med Suisse. 2013 Nov 20;9(407):2184-8. French.

PMID:
24354254
11.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.

12.

Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.

Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.

Endocr Relat Cancer. 2013 May 21;20(3):403-13. doi: 10.1530/ERC-12-0402. Print 2013 Jun.

13.

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.

Virchows Arch. 2012 Aug;461(2):157-62. doi: 10.1007/s00428-012-1270-7. Epub 2012 Jul 6.

PMID:
22767266
14.

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.

PMID:
22473923
15.

Advancing a clinically relevant perspective of the clonal nature of cancer.

Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12054-9. doi: 10.1073/pnas.1104009108. Epub 2011 Jul 5.

16.

Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L.

J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828. Epub 2011 Jan 5.

PMID:
21294127
17.

Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?

Hailemariam S, Vosbeck J, Cathomas G, Zlobec I, Mattarelli G, Eichenberger T, Zellweger T, Bachmann A, Gasser TC, Bubendorf L.

Hum Pathol. 2011 May;42(5):702-9. doi: 10.1016/j.humpath.2010.09.006. Epub 2011 Jan 15.

PMID:
21237492
18.

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.

Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L.

Int J Cancer. 2009 Jun 15;124(12):2899-904. doi: 10.1002/ijc.24258.

19.

Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.

Zellweger T, Günther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rüfenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L.

Int J Cancer. 2009 May 1;124(9):2116-23. doi: 10.1002/ijc.24174.

20.

Stat3 promotes metastatic progression of prostate cancer.

Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT.

Am J Pathol. 2008 Jun;172(6):1717-28. doi: 10.2353/ajpath.2008.071054. Epub 2008 May 15.

21.

Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.

Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT.

Cancer Res. 2008 Jan 1;68(1):236-48. doi: 10.1158/0008-5472.CAN-07-2972.

22.

Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.

Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT.

Endocrinology. 2007 Jul;148(7):3089-101. Epub 2007 Apr 5.

PMID:
17412813
23.

[Multiprobe FISH for enhanced prediction of recurrent bladder cancer].

Zellweger T, Benz G, Herzog M, Grilli B, Mihatsch MJ, Gasser TC, Bubendorf L.

Verh Dtsch Ges Pathol. 2004;88:194-8. German.

PMID:
16892552
24.

Ureteral obstruction after dextranomer/hyaluronic acid copolymer injection for treatment of secondary vesicoureteral reflux after renal transplantation.

Seifert HH, Mazzola B, Zellweger T, Ruszat R, Muller A, Burkhalter F, Steiger J, Sulser T, Bachmann A.

Urology. 2006 Jul;68(1):203.e17-9.

PMID:
16808962
25.

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.

Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser TC, Bubendorf L.

Int J Cancer. 2006 Oct 1;119(7):1660-5.

26.

[How to treat a localized prostate cancer: irradiation, surgery or watchful waiting?].

Zellweger T, Gasser T.

Praxis (Bern 1994). 2005 Aug 24;94(34):1307-8. Review. German. No abstract available.

PMID:
16170999
27.

Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.

Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT.

Clin Cancer Res. 2005 Aug 15;11(16):5863-8.

28.

Expression patterns of potential therapeutic targets in prostate cancer.

Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L.

Int J Cancer. 2005 Feb 10;113(4):619-28.

29.

Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model.

Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME.

BJU Int. 2003 Sep;92(4):463-9.

30.

Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.

Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.

Cancer Res. 2003 Jul 1;63(13):3575-84.

31.

Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.

Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L.

Prostate. 2003 Apr 1;55(1):20-9.

PMID:
12640657
32.

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME.

Clin Cancer Res. 2002 Oct;8(10):3276-84.

33.

Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S.

Invest New Drugs. 2002 May;20(2):145-58. Review.

PMID:
12099575
34.

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.

July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME.

Prostate. 2002 Feb 15;50(3):179-88.

PMID:
11813210
35.

Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells.

Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I.

Mol Urol. 2001 Autumn;5(3):105-11.

PMID:
11690557
36.

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.

Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME.

Neoplasia. 2001 Jul-Aug;3(4):360-7.

37.

Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME.

J Pharmacol Exp Ther. 2001 Sep;298(3):934-40.

38.
40.

Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa).

Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, Ackermann D, Schmid U, Moch H, Mihatsch MJ, Gasser TC, Sauter G.

Cancer Res. 1999 Sep 15;59(18):4658-61.

41.

Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer.

Wagner U, Süess K, Luginbühl T, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knönagel H, Rist M, Jordan P, Moch H, Mihatsch MJ, Gasser TC, Sauter G.

J Pathol. 1999 May;188(1):44-50.

PMID:
10398139
42.

Polysomies but not Y chromosome losses have prognostic significance in pTa/pT1 urinary bladder cancer.

Neuhaus M, Wagner U, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knönagel H, Rist M, Moch H, Mihatsch MJ, Gasser TC, Sauter G.

Hum Pathol. 1999 Jan;30(1):81-6.

PMID:
9923932
43.

The CONSORT statement.

Junker C, Egger M, Schneider M, Zellweger T, Antes G.

JAMA. 1996 Dec 18;276(23):1876-7; author reply 1877. No abstract available.

PMID:
8968009
44.

Randomised trials in German-language journals.

Egger M, Zellweger T, Antes G.

Lancet. 1996 Apr 13;347(9007):1047-8. No abstract available.

PMID:
8606592

Supplemental Content

Loading ...
Support Center